Investment Rating - The report maintains a "Strong Buy" rating for the company [4]. Core Insights - The company has shown continuous strong performance, with significant growth in both domestic and international business segments. In the first half of 2025, it achieved revenue of 387 million yuan and a net profit of 84 million yuan, representing year-on-year growth of 29.38% and 47.81% respectively [1]. - The domestic business is performing robustly, with a revenue increase of 36.7% in the first half of 2025, while international revenue also grew by 22.9% [8]. - The company is benefiting from the increasing emphasis on early-stage research and development in the biopharmaceutical sector, leading to a sustained upward trend in revenue and profit margins over the past three quarters [8]. - The company has successfully developed nearly 60 high-quality GMP-grade products, with significant sales growth in core recombinant protein varieties and other clinical products [8]. - The report projects a positive outlook for the company's net profit, estimating 182 million yuan, 237 million yuan, and 299 million yuan for 2025, 2026, and 2027 respectively, with corresponding PE ratios of 53, 41, and 33 [8]. Financial Data and Valuation - The company is expected to achieve total revenue of 839 million yuan in 2025, with a year-on-year growth rate of 30% [3]. - The projected net profit for 2025 is 182 million yuan, reflecting a 47% increase compared to the previous year [3]. - The current stock price is 57.83 yuan, with a total market capitalization of 9.7 billion yuan [4]. - The company has a low debt-to-asset ratio of 9.3%, indicating strong financial stability [4]. Performance Metrics - The company has shown a significant increase in quarterly revenue, with Q2 2025 revenue reaching 201 million yuan, a 30.95% increase year-on-year [1]. - The gross profit margin remains stable at around 90.5%, indicating strong pricing power and cost management [10]. - The return on equity (ROE) is projected to improve from 5.8% in the trailing twelve months to 9.9% by 2027 [4][10].
百普赛斯（301080）：业绩持续亮眼，国内业务继续维持高增